A cancer medicine in India can cost ₹8 to make available to a stockist and ₹64 to the patient. The National Pharmaceutical Pricing Authority's own market analysis found an average mark-up of about 170% on non-scheduled anti-cancer drugs, reaching 700% or more in some products.
On 8 October 2026 the Government approved a cap on that mark-up: 30% of the Maximum Retail Price. The expected effect is a fall in prices of up to 70% and savings of ₹2,500 crore a year for patients.
Two instruments, routinely confused
Almost everything written about Indian drug price control conflates two completely different tools. Getting them apart is the whole of this story.
| Ceiling price | Trade Margin Rationalisation | |
|---|---|---|
| Applies to | Scheduled formulations — those in Schedule I of DPCO 2013, drawn from the National List of Essential Medicines | Non-scheduled formulations — everything outside that list |
| What is fixed | The price itself. NPPA notifies a ceiling above which the medicine may not be sold | The margin between the price at which the trade buys and the MRP |
| Manufacturer's freedom | Constrained — the ceiling binds | Unconstrained — the ex-factory price remains free |
| Otherwise applicable limit | — | Non-scheduled drugs face only an annual cap on price increases |
The measure announced on 8 October is of the second kind. Essential cancer medicines inside the schedule were already under ceiling prices. What the Government has done is extend protection to the non-scheduled ones — and it has done so not by fixing their prices but by limiting what can be added to them on the way to the patient.
Why cap the margin instead of the price
Because the NPPA's finding tells you where the money is going.
If a medicine were expensive because its manufacturer charged a high ex-factory price, a ceiling price would be the right instrument. But a mark-up averaging 170% and running to 700% says the inflation happens after the manufacturer sells — in the chain of stockists, distributors and retailers between the factory and the patient. A cap on trade margins targets that directly.
It also avoids a much larger fight. Bringing every expensive branded or patented cancer drug into the schedule and fixing its price would be a far bigger intervention, legally contestable and politically fraught, and it carries a real risk that a price-controlled product simply stops being supplied. Capping the margin is the lighter-touch tool, and it is aimed at the specific pathology the data identifies.
The release also records that prices vary significantly depending on whether a medicine is bought from a retail pharmacy, a hospital pharmacy or an online pharmacy. That variation is itself a finding: the same medicine can carry different prices only when the MRP sits far above the cost of making it available. A margin cap compresses that spread.
The arithmetic worth being able to do
A cap of 30% of MRP is not the same as a 30% mark-up, and the difference confuses people.
Take a medicine with an MRP of ₹100. If the trade may retain no more than 30% of the MRP, the price to the stockist must be at least ₹70. Expressed from the distributor's side, that is a mark-up of about 43% on what the trade pays (30 ÷ 70). The same rule reads as 30% looking down from the MRP and 43% looking up from the purchase price.
Now the honest reading of the headline. A 70% price reduction is what you would expect at the extreme — a product currently carrying a 700% mark-up, where almost all of the MRP is margin. At the average mark-up of 170%, the fall is considerably smaller. "Up to 70%" describes the worst cases rather than the typical one, and the aggregate figure of ₹2,500 crore a year is the more defensible number to quote.
And the structural limit: a trade-margin cap constrains the distributor, not the manufacturer. Nothing in it prevents a company from raising its ex-factory price, in which case 30% is simply 30% of a larger MRP. TMR works where the margin is the problem. It does comparatively little where a drug is expensive because its maker prices it high.
What has not happened yet
The release is precise about this, and it is the detail to carry away: nothing is notified.
An expert committee under the Directorate General of Health Services (DGHS) will finalise the list of medicines to be covered. The National Pharmaceutical Pricing Authority will then take a decision and issue the notification. Until that happens, no particular medicine is subject to the cap.
So the accurate position on 8 October is that the Government has approved the approach and set the rate, and the coverage remains to be settled. Numbers of drugs circulating in press coverage run ahead of the official text. The thing to watch is the NPPA notification.
Para 19, and why this keeps being an emergency
Trade margin rationalisation is not done under the ordinary price-fixing machinery. It rests on the extraordinary powers in paragraph 19 of the Drugs (Prices Control) Order, 2013, which allows the Government, in the public interest and in circumstances it considers appropriate, to fix the price of any drug — including one outside the schedule.
That is both the tool's strength and its weakness. Its strength is reach: it lets the Government act on a non-scheduled medicine without the long process of revising the NLEM. Its weakness is that it is framed as an exception. A Para 19 order is an exceptional measure, typically time-limited, and each exercise of the power is separately open to challenge.
Which is why the first use of it on cancer drugs, in February 2019, was described as a pilot. That exercise brought 42 non-scheduled anti-cancer drugs under a 30% trade-margin cap, and the Government's later assessment credited it with substantial reductions in MRP across several hundred brands and savings of the order of a few hundred crore rupees a year — figures that vary between official summaries and should be cited with that caution.
Seven years on, the Government is doing it again, at the same rate, on a larger list. A tool used repeatedly as an emergency is a tool that arguably ought to be a standing rule, and the question of giving trade margin rationalisation a permanent statutory basis within the DPCO has been raised in parliamentary scrutiny of the sector. That is the reform worth watching beyond this notification.
Why cancer, and why price rather than insurance
Cancer incidence in India is around 60 per lakh population, and treatment is the paradigm case of catastrophic health expenditure: therapy runs for months or years, the medicines are expensive, and they are frequently not substitutable. The release notes that State authorities including those in Maharashtra, Rajasthan and Karnataka, along with patients and civil society, had raised concerns about the gap between the price at which medicines are bought for sale and the MRP charged to patients.
India's health-financing problem is that a large share of spending happens out of pocket at the point of care, and medicines are the single biggest component of it. That is the reason a price measure matters alongside an insurance measure, and the two are complements rather than substitutes: insurance changes who pays the bill; price control changes the size of the bill. A scheme that reimburses an inflated price transfers the inflation to the exchequer rather than removing it, which is why the Ayushman Bharat architecture and the DPCO are two halves of one answer.
There is a third lever, and it is the cheapest of all. Preventing a cancer costs a fraction of treating one, which is the economic case behind the HPV vaccination programme against cervical cancer. Prevention, price and insurance act on the same burden at three different points, and the household data in NFHS-6 is where their combined effect eventually shows up.
🔑 Revision block
- Decision, 8 October 2026: the Government approved a cap on trade margins for non-scheduled anti-cancer drugs at 30% of MRP. Expected to cut prices by up to 70% and save patients ₹2,500 crore annually.
- Process pending: an expert committee under the Directorate General of Health Services (DGHS) will finalise the list of medicines; the National Pharmaceutical Pricing Authority (NPPA) will then decide and issue the notification. Nothing is notified yet.
- Two instruments, distinguished: ceiling price applies to scheduled formulations in Schedule I of DPCO 2013, drawn from the National List of Essential Medicines, and fixes the price. Trade Margin Rationalisation applies to non-scheduled formulations and caps the margin between the trade's purchase price and the MRP; the manufacturer's ex-factory price stays free.
- Why a margin cap: NPPA market analysis found an average mark-up of about 170% on non-scheduled anti-cancer drugs, reaching 700% or more in some. The inflation occurs after the manufacturer sells, so the chain — not the ex-factory price — is the target. It also avoids the larger fight over fixing prices of branded and patented medicines, and the supply risk that carries.
- The arithmetic: a cap of 30% of MRP means for an MRP of ₹100 the price to the stockist must be at least ₹70 — equivalently a mark-up of about 43% on the purchase price (30 ÷ 70).
- Read the headline honestly: a 70% reduction corresponds to the extreme cases (700% mark-up). At the average 170% mark-up the fall is much smaller. ₹2,500 crore is the more defensible figure.
- The structural limit: a margin cap binds the distributor, not the manufacturer. Nothing prevents a higher ex-factory price, in which case 30% is 30% of a larger MRP.
- Legal basis: paragraph 19 of the DPCO, 2013 — extraordinary powers allowing the Government to fix the price of any drug in the public interest, including non-scheduled ones. Strength: reach without revising the NLEM. Weakness: it is an exception, typically time-limited and separately challengeable — hence calls to give TMR a permanent statutory basis in the DPCO.
- The 2019 precedent: February 2019, 42 non-scheduled anti-cancer drugs brought under a 30% trade-margin cap under Para 19, described officially as a pilot. Reported savings and brand counts vary between official summaries.
- Non-scheduled drugs otherwise face only a cap on the annual increase in price, not on the price itself.
- Burden: cancer incidence around 60 per lakh population. Prices vary by retail pharmacy, hospital pharmacy and online pharmacy — possible only where MRP sits far above the cost of supply. Concerns were raised by Maharashtra, Rajasthan and Karnataka, patients and civil society.
- Three levers on the same burden: prevention (vaccination and screening), price (DPCO ceiling prices and TMR), insurance (Ayushman Bharat). Insurance changes who pays; price control changes how much. Reimbursing an inflated price moves the inflation to the exchequer rather than removing it.
- Institutions: NPPA fixes prices and notifies, under the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers. DGHS sits under the Ministry of Health and Family Welfare.
🎯 Practice MCQs
Q1. Ceiling prices under the Drugs (Prices Control) Order, 2013, apply to: (a) All drugs sold in India (b) Scheduled formulations listed in Schedule I, drawn from the National List of Essential Medicines (c) Only patented medicines (d) Only medicines procured by government hospitals
→ (b) Scheduled formulations are price-capped directly. Everything outside the schedule is non-scheduled and faces only a limit on annual price increases, unless an extraordinary power is used.
Q2. Trade Margin Rationalisation differs from a ceiling price in that it: (a) Caps the margin between the trade's purchase price and the MRP, leaving the manufacturer's price free (b) Fixes the manufacturer's ex-factory price (c) Applies only to imported medicines (d) Requires the medicine to be added to the NLEM first
→ (a) Which is precisely why it suits a case where the mark-up, rather than the manufacturer's price, is driving the final cost.
Q3. The legal basis for capping the price of a non-scheduled drug in the public interest is: (a) Section 3 of the Essential Commodities Act, 1955 (b) The Drugs and Cosmetics Act, 1940 (c) The Patents Act, 1970 (d) Paragraph 19 of the DPCO, 2013
→ (d) Para 19 confers extraordinary powers to fix the price of any drug in the public interest — the route used for trade margin rationalisation, both in 2019 and now.
Q4. The principal structural weakness of relying on Para 19 for trade margin rationalisation is that: (a) It applies only to drugs manufactured in India (b) It requires the consent of the State governments (c) It cannot be used for cancer medicines (d) It is an exceptional power, typically time-limited and separately open to challenge
→ (d) Which is why giving trade margin rationalisation a permanent statutory basis within the DPCO has been pressed in parliamentary scrutiny.
Q5. NPPA's analysis found that non-scheduled anti-cancer medicines carried an average mark-up of approximately: (a) 170%, reaching 700% or more in some cases (b) 30%, reaching 70% in some cases (c) 43%, reaching 100% in some cases (d) 500%, uniformly across products
→ (a) The 30% figure is the new cap and the 70% figure is the expected maximum price reduction — neither is the observed mark-up.
Q6. If the trade margin on a medicine is capped at 30% of its MRP, the price at which the trade buys it must be at least: (a) 30% of the MRP (b) 43% of the MRP (c) 70% of the MRP (d) 57% of the MRP
→ (c) ₹70 on an MRP of ₹100 — which from the distributor's side is a mark-up of about 43% on the purchase price.
Q7. As of the announcement, which of the following was still to be completed? (a) Fixing the rate of the margin cap (b) Approval of the measure by the Government (c) Finalisation of the list of covered medicines by a DGHS expert committee, followed by NPPA notification (d) Amendment of the National List of Essential Medicines
→ (c) The approach and the rate are settled; the coverage is not, and no medicine is subject to the cap until NPPA notifies.
Q8. The 2019 precedent for this measure covered: (a) All non-scheduled medicines (b) 42 non-scheduled anti-cancer drugs (c) 131 scheduled anti-cancer formulations (d) Only oncology medicines procured under Ayushman Bharat
→ (b) Forty-two drugs at a 30% cap, under Para 19, and described officially at the time as a pilot.
Q9. The main limitation of a trade margin cap as a price-control instrument is that it: (a) Applies only to generic medicines (b) Reduces the quality of medicines supplied (c) Cannot be enforced against retailers (d) Constrains the distributor but not the manufacturer's ex-factory price
→ (d) If the manufacturer raises its price, the capped 30% is simply 30% of a larger MRP — so the tool suits cases where the margin is the pathology.
Q10. Price control and health insurance are complementary rather than substitutable because: (a) Insurance changes who pays the bill, while price control changes its size (b) Insurance covers only inpatient care, and price control only outpatient care (c) Price control applies only to government hospitals (d) Insurance schemes are not permitted to reimburse scheduled drugs
→ (a) A scheme that reimburses an inflated price transfers the inflation to the exchequer rather than eliminating it, which is why both levers are used on the same burden.
📋 How this gets asked (PYQ pattern)
Drug pricing is examined in four recognisable ways, and the first is a distinction most candidates have never been taught.
The first is ceiling price versus trade margin. Scheduled formulations under Schedule I of DPCO 2013 get a notified ceiling price; non-scheduled ones can get a margin cap under Para 19. A statement saying the Government has "fixed the price" of a non-scheduled cancer drug is wrong, and that is the planted error.
The second is institution-to-function mapping. NPPA fixes and notifies prices, under the Department of Pharmaceuticals in the Ministry of Chemicals and Fertilizers; DGHS sits under Health and Family Welfare; the NLEM is prepared by the health ministry and feeds Schedule I. Three bodies, two ministries, and the NPPA's parent ministry is the detail most often got wrong.
The third is the numbers. 30% cap, 170% average mark-up, 700% maximum, up to 70% expected price fall, ₹2,500 crore annual savings, 42 drugs in 2019, 60 per lakh incidence. Know which number is the cap, which the observed mark-up and which the projected saving — the question will swap two of them.
The fourth, and the one that makes a written answer, is the three-lever argument. Explaining how prevention, price regulation and insurance act on catastrophic health expenditure at different points, and why reimbursing an inflated price does not solve it, demonstrates understanding of health financing rather than recall of a scheme.
Preparing for CDS/OTA? When a price measure is announced, ask what exactly is being capped — the price, the margin, or the rate of increase. Those three are different instruments with different limits, and the question almost always turns on which one is in play. Build the base with our CDS/OTA study material and the economy section, follow the daily CDS current affairs, and prepare with our faculty in the upcoming Cavalier courses in Delhi.
✍️ Written by Hitendra Deswal — Faculty, Economy & Polity, at The Cavalier. Reviewed by the Cavalier Faculty Desk.